23andMe has been quietly exploring a possible sale of its telehealth business, Lemonaid
The struggling genetic-testing 23andMe is looking for a buyer for the virtual-care business it acquired in 2021, Business ...
23andMe is exploring strategic alternatives, looking to raise capital
23andMe said it's started exploring strategic alternatives, including a possible sale. The company released third-quarter ...
23andMe Board Explores Strategic Alternatives Amid Restructuring
23andMe Holding Co. ( ME, Financials) announced that its board's Special Committee is reviewing strategic alternatives, ...
Nature8d
What went wrong at 23andMe? Why the genetic-data giant risks collapse
At-home DNA testing is no longer in high demand — and critics have raised concerns about unreliable tests and privacy.
Business Insider19d
What went wrong for 23andMe
23andMe CEO Anne Wojcicki sounded optimistic about the company's future during an earnings call in February last year. She said the biotech company, which offers direct-to-consumer genetic testing ...
Law27d
If 23andMe Goes Bankrupt, What Happens to All Our Data?
But there are facts, law and precedent on point, which are worth examining. First, we can start with 23andMe’s privacy statement, which is—to their credit—strong. In general, data can be ...
Genetic test maker 23andMe eyes strategic alternatives, including a sale
Genetic testing pioneer 23andMe is looking at strategic alternatives, including a possible sale, it said Tuesday, months ...
23andMe reports Q3 cont ops EPS ($1.02) vs. ($10.80) last year
Reports Q3 revenue $60.3M vs. $44.75M last yearInvest with Confidence: Follow TipRanks' Top Wall Street Analysts to uncover their success rate ...